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ril 2, 2013.his study sought to explore the incidence and risk factors of thromboembolic complications after cardioversion of
acute atrial ﬁbrillation.Background Anticoagulation therapy is currently recommended after cardioversion of acute atrial ﬁbrillation in patients with risk
factors for stroke, but the implementation of these new consensus-based guidelines has been slow.Methods A total of 7,660 cardioversions were performed in 3,143 consecutive patients with atrial ﬁbrillation lasting <48 h in
3 hospitals. For this analysis, embolic complications were evaluated during the 30 days after 5,116 successful
cardioversions in 2,481 patients with neither oral anticoagulation nor peri-procedural heparin therapy.Results There were 38 (0.7%; 95% conﬁdence interval [CI]: 0.5% to 1.0%) deﬁnite thromboembolic events (31 strokes)
within 30 days (median 2 days, mean 4.6 days) after cardioversion. In addition, 4 patients suffered transient
ischemic attack after cardioversion. Age (odds ratio [OR]: 1.05; 95% CI: 1.02 to 1.08), female sex (OR: 2.1; 95%
CI: 1.1 to 4.0), heart failure (OR: 2.9; 95% CI: 1.1 to 7.2), and diabetes (OR: 2.3; 95% CI: 1.1 to 4.9) were the
independent predictors of deﬁnite embolic events. Classiﬁcation tree analysis showed that the highest risk of
thromboembolism (9.8%) was observed among patients with heart failure and diabetes, whereas patients with no
heart failure and age <60 years had the lowest risk of thromboembolism (0.2%).Conclusions The incidence of post-cardioversion thromboembolic complications is high in certain subgroups of patients when no
anticoagulation is used after cardioversion of acute atrial ﬁbrillation. (Safety of Cardioversion of Acute Atrial
Fibrillation [FinCV]; NCT01380574) (J Am Coll Cardiol 2013;62:1187–92) ª 2013 by the American College of
Cardiology FoundationAnticoagulation is recommended for 3 weeks before and 4
weeks after cardioversion for patients with atrial ﬁbrillation of
unknown duration or duration >48 h (1–3). Systemic em-
bolism might also occur with shorter duration of arrhythmia,
but the need for anticoagulation is less clear, and it has been
a common practice to cardiovert acute (<48 h) atrial ﬁbrilla-
tion without anticoagulation (4–6). This practice has been
recently called into question, and recent guidelines recom-
mend anticoagulation therapy during and after cardioversionversity Hospital, Turku, Finland; yDivision of
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3; revised manuscript received March 28, 2013,in patients with acute atrial ﬁbrillation and risk factors for
stroke (1).
Because the new recommendations are based mainly on
consensus, and no randomized trials are available, we decided
to evaluate the incidence and risk factors of thromboembolic
complications after successful cardioversion of acute atrial
ﬁbrillation when no anticoagulation is used.
See page 1193
Methods
All patients with a primary diagnosis of atrial ﬁbrillation
(ICD-10 code I48) were identiﬁed from the institutional
discharge registries in the 3 participating hospitals. Emer-
gency clinic admission records and databases were then used
to review all patients (>18 years of age) with acute (<48 h)
atrial ﬁbrillation who underwent cardioversion during the
study period. In addition, only patients living in the hospital
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1188catchment area were included to
get the adequate follow-up data
after the cardioversion. Each of
these 3 hospitals is the only
referral hospital responsible for
the acute care of patients with
cardiac and stroke events in their
catchment areas.A total of 7,660 consecutive cardioversions were identiﬁed
in 3,143 patients with acute (<48 h) atrial ﬁbrillation treated
at the emergency clinics of 2 university hospitals from 2003
through 2010 and 1 central hospital during 2010 (see trial
registry data note following abstract). Of the 7,237 successful
cardioversions, 5,116 were performed without peri-procedural
and post-cardioversion oral anticoagulation or heparin, and
these cardioversions were included in the present analysis.
Total number of the included patients was 2,481.
Diagnosis of atrial ﬁbrillation was conﬁrmed by 12-lead
electrocardiography according to the standard criteria. All
cardioversion procedures were performed with electrocar-
diographic monitoring and full resources for cardiopulmo-
nary resuscitation. Electrocardiogram was recorded before
and after the procedure to verify the changes in cardiac
rhythm. Cardioversion was considered successful if sinus
rhythm was restored and the patient was discharged from
the cardioversion unit in sinus rhythm.
All case records were reviewed with standardized data
collection protocol to get information on baseline charac-
teristics and medication of the patients and management of
the patients during the index cardioversion and during a
30-day follow-up after cardioversion. All possible throm-
boembolic and bleeding complications, death, and any
conditions that caused the patient to consult a physician
within 30 days after the cardioversion were recorded. The
duration of the index arrhythmia was determined from the
symptom history in the patient records and the exact time of
cardioversion.
The primary study outcome measure was deﬁnite throm-
boembolic event within 30 days after index cardioversion.
Deﬁnite thromboembolic event was deﬁned as a stroke
documented clinically and conﬁrmed by computerized
tomography or magnetic resonance imaging to be caused by
cerebral infarction or a systemic embolism conﬁrmed by
imaging, surgery, or autopsy. Probable embolic complications
included transient ischemic attacks that were not conﬁrmed
by imaging or other embolism suspected clinically but not
conﬁrmed by imaging. After completion of manual regis-
tration of data, a computer-based cross-checking of strokes
was performed from discharge register data of the included
patients to ensure the complete coverage of all events.
Bleedings were deﬁned according to the Thrombolysis In
Myocardial Infarction criteria (7). All potential outcome
measures were classiﬁed by at least 2 members of the study
team.
The study protocol was approved by the Medical Ethics
Committee of the Hospital District of Southwest Finlandand the ethics committee of the National Institute for
Health and Welfare. Informed consent was not required,
because of the register-based nature of the study. The study
complies with the Declaration of Helsinki.
Statistical analyses were performed with SPSS software
(version 20.0, SPSS, Inc., Chicago, Illinois) and SAS software
(version 9.2, SAS Institute, Inc., Cary, North Carolina).
Continuous variables were tested for normal distribution by
the Kolmogorov-Smirnov test. Data are presented as mean
 SD, median (interquartile range), or absolute number and
percentages, as appropriate. Chi-square and Fisher exact tests
were used to compare differences between proportions.
Student t test andMann-WhitneyU test were used for analysis
of continuous data. Differences were considered signiﬁcant if
the null hypothesis could be rejected at the 0.05 probability
level. Rates of embolic events were calculated by dividing the
number of events by the number of procedures. Because the
primary study outcomewas binary and repeated cardioversions
of same individuals were included in analyses, theGENMOD
procedure with repeated measures option was used in the
univariate and multivariate analyses. After the univariate
analyses, a logistic multivariable regression analysis was per-
formed to identify independent predictors for deﬁnite
thromboembolism. Because of multiple testing, only variables
with a 2-sided p value <0.05 in the univariate analysis were
accepted for themodel. Classiﬁcation tree analysis was used for
classiﬁcation of the risk for thromboembolism according to the
independent risk factors. Validation of the classiﬁcation tree
procedure was assessed by cross-validation through 25 folds.
The minimum number of patients for parent node was set to
50, and the minimum for child node was 10. The maximum
classiﬁcation tree depth was 5. We chose the chi-square
automatic interaction detection method, and its best model
on the basis of the obtained predicted probabilities. Minimum
change in improvement was set at a signiﬁcance level of 0.05.
Receiver-operating characteristics (ROC) curve analysis was
employed for estimating of the area under the curve of
probabilities of regression models and to assess the ability of
risk-scoring methods in predicting post-procedural thrombo-
embolism. A p < 0.05 was considered statistically signiﬁcant.
Results
Cardioversion was successful in 5,116 (95.4%) of the 5,362
procedures in 2,481 patients who had no peri-procedural
oral anticoagulation or heparin therapy. A great majority
(88%) of cardioversions were electrical (Table 1). The mean
age of patients averaged 61.0  12.4 (median 62) years, and
1,580 (63.7%) were men. The baseline characteristics of the
patients according to the incidence of deﬁnite thromboem-
bolic complications are described in Table 1.
Thirty-eight deﬁnite embolic events occurred in 38
patients (0.7% of successful procedures; 95% conﬁdence
interval [CI]: 0.5% to 1.0%), and 31 of these were strokes.
One patient experienced both stroke and systemic embolism.
Four additional patients suffered from a transient ischemic
Table 1
Clinical Characteristics of Patients With and Without Deﬁnite Thromboembolic
Complications After Cardioversion
No Complications
(5,078 Cardioversions,
2,459 Patients)
Embolic Complications
(38 Cardioversions,
38 Patients) p Value
Age (yrs) 60.9  12.4 69.9  9.3 <0.0001
Female 1,616 (31.8) 22 (57.9) 0.0006
Hypertension 2,305 (45.4) 19 (50.0) 0.57
Diabetes 401 (7.9) 8 (21.1) 0.009
Vascular disease 1,128 (22.2) 17 (44.7) 0.0009
History of myocardial infarction 323 (6.4) 6 (15.8) 0.03
Aspirin or clopidogrel 2,445 (48.1) 25 (65.8) 0.03
Heart failure 178 (3.5) 6 (15.8) 0.002
History of thromboembolism 288 (5.7) 3 (7.9) 0.48
CHADS2 score 1 (0–1) 1 (0–2) 0.006
0–1 4,239 (83.5) 25 (65.8)
2 575 (11.3) 5 (13.2)
3–6 264 (5.2) 8 (21.1)
CHA2DS2VASc score 1 (0–3) 3 (1–4) <0.0001
0–1 2,668 (52.5) 10 (26.3)
2 1,027 (20.2) 3 (7.9)
3–5 1,263 (24.9) 21 (55.3)
>5 116 (2.3) 4 (10.5)
Cardioversions/patient, n 1 (1–2) 1 (1–3) 0.82
1 1,479 (60.5) 22 (57.9)
2–5 828 (33.9) 16 (42.1)
>5 136 (5.6) 0 (0)
Electrical cardioversion 4,452 (87.7) 36 (94.7) 0.32
No previous history of atrial ﬁbrillation 1,462 (28.8) 11 (29.0) 0.98
Duration of symptoms <24 h 4,251 (83.7) 29 (76.3) 0.22
Beta-blockers 3,774 (74.3) 34 (89.5) 0.04
Digoxin 274 (5.4) 4 (10.5) 0.15
Verapamil 63 (1.2) 0 (0) 1.00
Amiodarone/dronedarone 104 (2.1) 0 (0) 1.00
Class I antiarrhythmic agents 1,172 (23.1) 8 (21.0) 0.72
Values are mean  SD, n (%), or median (interquartile range).
CHADS2 ¼ Congestive heart failure, Hypertension, Age 75, Diabetes mellitus, and prior Stroke or transient ischemic attack (doubled);
CHA2DS2VASc ¼ Congestive heart failure, Hypertension, Age 75 (doubled), Diabetes mellitus, and prior Stroke, transient ischemic attack or
thromboembolism (doubled), Vascular disease, Age 65 to 74, Sex category (female).
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1189attack after cardioversion (mean 2 days). The deﬁnite embolic
events occurred between 1 and 27 days after cardioversion
(median 2 days, mean 4.6 days).
Two patients suffered from pulmonary embolism, and
there were 11 deaths during the 30-day follow-up (median
3 days, mean 7 days after cardioversion), including 3 patients
with fatal stroke. One patient died of aortic dissection, which
occurred within 24 h of cardioversion but was unlikely to be
related to the cardioversion. There were no major bleeding
complications during the follow-up, and the only clinically
relevant bleeding event was related to surgical embolectomy.
Logistic regression analyses showed that age (odds ratio
[OR]: 1.05; 95% CI: 1.02 to 1.08, p < 0.001), female sex
(OR: 2.1; 95% CI: 1.1 to 4.0, p ¼ 0.03), heart failure (OR:
2.9; 95% CI: 1.1 to 7.2, p ¼ 0.03), and diabetes (OR: 2.3;
95% CI: 1.1 to 4.9, p ¼ 0.03) were the only independent
predictors of embolic events (Table 2).
Chi-square automatic interaction detection analysis
showed that heart failure, diabetes, and age >60 years werepredictive of post-procedural deﬁnite thromboembolism
(area under the ROC curve: 0.68, 95% CI: 0.60 to 0.76)
(Fig. 1). A cutoff of 60 years was chosen on the basis of
ROC curve analysis and the results of classiﬁcation tree
analysis. The highest risk of thromboembolism (9.8%) was
observed in patients with heart failure and diabetes, whereas
patients without heart failure and <60 years of age had the
lowest risk of thromboembolism (0.2%).
There were 246 failed cardioversions in patients with no
peri- or post-procedural anticoagulation. None of these
patients suffered from thromboembolic complications
during the 30-day follow-up.
Discussion
Our results show that, in general, embolic events are quite rare
(<1%) within 30 days after cardioversion of acute atrial
ﬁbrillation, even without perioperative anticoagulation. The
incidence of thromboembolism is within the same range as
Table 2
Univariate and Multivariate Predictors of Deﬁnite Thromboembolism After Cardioversion
for Atrial Fibrillation
Univariate Analysis Multivariate Analysis
OR (95% CI) p Value OR (95% CI) p Value
Age 1.07 (1.04–1.10) <0.001 1.05 (1.02–1.08) <0.001
Female 2.95 (1.54–5.65) 0.001 2.06 (1.06–3.98) 0.03
Heart failure 5.17 (2.02–13.20) <0.001 2.85 (1.12–7.24) 0.03
Diabetes 3.11 (1.41–6.89) 0.005 2.28 (1.07–4.87) 0.03
Vascular disease 2.82 (1.48–5.40) 0.002 1.61 (0.82–3.15) 0.17
Aspirin or clopidogrel 2.07 (1.05–4.07) 0.04
CI ¼ conﬁdence interval; OR ¼ odds ratio.
Airaksinen et al. JACC Vol. 62, No. 13, 2013
Stroke and Cardioversion of Atrial Fibrillation September 24, 2013:1187–92
1190in unselected patients undergoing elective or acute car-
dioversion during therapeutic anticoagulation (3,8). However,
increasing age, female sex, heart failure, and diabetes increase
the risk of thromboembolic complications substantially, and in
the presence of multiple risk factors, the risk becomes unac-
ceptably high (approximately 10%), signiﬁcantly higher than
after elective cardioversion of atrial ﬁbrillation when using
conventional pre- and post-cardioversion anticoagulation
(Fig. 1). Interestingly, both of the recommended stroke risk
scores (Congestive heart failure, Hypertension, Age 75,
Diabetesmellitus, andprior Stroke or transient ischemic attack
[doubled]; and Congestive heart failure, Hypertension,
Age 75 [doubled], Diabetes mellitus, and prior Stroke,
transient ischemic attack, or thromboembolism [doubled],
Vascular disease, Age 65 to 74, Sex category [female]) were
highly predictive for thromboembolism also in this acute
setting (Table 1) (9,10).
Most embolic events occurred shortly after successful
cardioversion, which supports the view that the conversion of
atrial arrhythmia to sinus rhythm is responsible for theFigure 1 Incidence of TE After Cardioversion
Variation of the risk of deﬁnite thromboembolic complications (TE) after cardioversion of
interaction detection analysis.thromboembolism also after short attacks (<48 h) of
arrhythmia (11). Indeed, transesophageal echocardiography
has shown that left atrial thrombida clear contraindication to
cardioversiondare found in 4% of the patients already within
the ﬁrst 48 h of atrial ﬁbrillation when no anticoagulation is
used (12). In the aforementioned study, low ejection fraction
turned out to be a signiﬁcant predictor for the presence of
thrombi, which is in line with our present observation on
heart failure as a major risk factor for post-cardioversion
embolism. Another study by Stoddard et al. (13) reported
a prevalence of 14% for left atrial thrombi when the duration
of arrhythmia was <72 h. It is also noteworthy that the
absence of thrombus before cardioversion does not guarantee
safe cardioversion, because restoration of sinus rhythm results
in a fall in blood ﬂow velocity of the left atrial appendage (14),
and it is now generally accepted that this accentuation of atrial
stasis promotes new thrombus formation and predisposes to
embolization. Our observations are in agreement with these
data and suggest that atrial stunning might also occur in the
setting of short attacks of atrial ﬁbrillation and render toacute (duration <48 h) atrial ﬁbrillation (AF), according to the chi-square automatic
Table 3
Thromboembolic Complications in Patients With No Anticoagulation After Cardioversion of
Acute (<48 h) Atrial Fibrillation in Previous Studies
First Author (Ref. #) n Mean Age, yrs Male Success Rate Thromboembolism
Weigner et al. (4) 224 68 NA 95% 0.9%*
Michael et al. (17) 217 64 54 86% 0.5%*
Burton et al. (15) 314 61 55 86% 0y
Gallagher et al. (5) 198 63 68 100% 0.5%z
Stiell et al. (18) 414 65 56 92% 0y
Xavier Scheuermeyer et al. (16) 104 57 92 96% 0
*All 3 thromboembolic events after spontaneous cardioversion and in elderly (>75 years) women. yFollow-up of 7 days. zPlus 1 probable thromboembolic
event.
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1191embolism especially when the patient has clinical features
favoring thrombus formation. Most of the embolic events in
this setting occurred within 3 to 4 days after cardioversion.
According to the case records, spontaneous conversion of
later recurrences of atrial ﬁbrillation seemed to be responsible
for at least 1 of the late (Day 27) thromboembolic events.
At the time of our study, European and American
guidelines did not have solid recommendations about anti-
coagulation in recent-onset (<48 h) atrial ﬁbrillation (2).
Thus, a general approach in our country was to convert atrial
ﬁbrillation without post-cardioversion oral anticoagulants as
long as there was a clear history of arrhythmia onset within
48 h from the scheduled cardioversion. This practice was
called into question in 2010 when the European guidelines
recommended effective perioperative and long-term anti-
coagulation in patients with risk factors for stroke (1). The
implementation of the guideline has been slow, because the
evidence behind the recommendation is circumstantial
and supported only by small retrospective cardioversion
studies. Furthermore, prolonged use of low-molecular
weight heparin to cover the start of warfarin treatment
causes signiﬁcant logistic problems in busy emergency
rooms. To the best of our knowledge, there are only 6 small
retrospective studies (n = >50) involving, in total, <1,500
patients shedding light on this issue (Table 3) (4,5,15–18).
The incidence of thromboembolic events in these studies has
been low, and all deﬁnite events occurred in elderly (age >75
years) women and after spontaneous conversion of
arrhythmia to normal sinus rhythm. Our present data
strongly support the new European recommendations.
Study limitations. Although our study is the ﬁrst to include
a meaningful number of consecutive patients for the decision
making, it has certain limitations. A retrospective study does
not allow characterization of the study cohort as accurately as
in a well-executed prospective trial. We were dependent on
the recording of data by the physicians who performed the
cardioversion and were responsible for the follow-up.
However, because of the good coverage of electronic patient
records and stability of the population, we could reliably
review the outcome from all included patients at the subse-
quent outpatient and hospital visits. An important limitation
was that the onset of atrial ﬁbrillation was based on onset of
symptoms. It is well-known that symptoms might not be
reliable for accurate marking of onset of atrial ﬁbrillation. Asexpected in some of the cases, there was uncertainty of the
exact time of arrhythmia onset especially during the night
time, but according to the recorded patient history it
was <48 h also in these cases. The multivariate model in the
classiﬁcation and regression trees analysis might be somewhat
overﬁtted, although only a small number of variables were
included in the models, and the results were cross-validated
25 times. All these limitations must be weighed against the
advantage that the retrospective design avoids ﬁltering and
yields results that reﬂect clinical practice more accurately than
those of a prospective study.Conclusions
Our results in this large multicenter, retrospective patient
cohort show that, although in general the risk of deﬁnite
thromboembolic events after cardioversion of acute atrial
ﬁbrillation is quite low, it becomes unacceptably high in
patients with conventional risk factors for thromboembolism.
Our results support the current recommendation that these
patients need effective peri-procedural anticoagulation fol-
lowed by long-term oral anticoagulation. At present, it seems
unethical to execute a randomized trial on anticoagulation in
the high-risk patients in this setting, and in patients with
a lower event rate the sample size would be several thousands
of cardioversions, making the study unattractive.Acknowledgments
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